Novel physiologiC prEdictors of Positive Airway Pressure effectiveness: NICE-PAP study.

气道正压有效性的新型生理预测因素:NICE-PAP 研究。

基本信息

  • 批准号:
    10284505
  • 负责人:
  • 金额:
    $ 17.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

Candidate. My goal is to become an independent physician-scientist who merges physiology and patient-ori- ented research methods to personalize care for patients with obstructive sleep apnea (OSA). My training as an engineer and a doctor in Pulmonary, Critical Care and Sleep Medicine (PCCSM), complemented by research training in epidemiology, have given me the background necessary to pursue this goal. I propose training activ- ities that will allow me to personalize treatments for one of the most pressing problems for OSA patients- effec- tiveness of continuous positive airway pressure (CPAP). Through coursework, externships and mentored expe- rience in physiologic and patient-oriented research, this training program will build skills and knowledge in 1) physiologic characterization of OSA, 2) treatment adherence, efficacy and patient-oriented outcomes, 3) conduct of clinical studies, 4) advanced biostatistics and 5) leading a research program. Executing this program will bridge current knowledge gaps related to the role of physiologic traits in CPAP effectiveness and set me up for success as an independent investigator. Mentors and Environment. I have engaged an exceptional team of mentors with expertise tailored for this proposal. My primary mentor, Dr. Yaggi, is a national expert in OSA epidemiology and clinical study conduct. My co-mentors are Dr. Wellman, a pioneer in translational OSA physiology, and Dr. Redeker, a leader in patient- centered outcomes sleep research. This proposal leverages a wealth of resources across institutions, including Yale’s Center for Precision Pulmonary Medicine and Clinical Epidemiology Research Center, Centers for Sleep Medicine, PCCSM Section and Internal Medicine Department. The Sleep Disordered Breathing laboratory led by Dr. Wellman at Harvard is a renowned OSA physiology center. This environment provides methodologic expertise, research tools and a venue to conduct cutting-edge patient-oriented research in sleep. Mentored Research Project. Most patients with OSA who are prescribed the gold-standard therapy, CPAP, are ineffectively treated. This is due to 1) poor CPAP adherence, 2) high residual apnea in 20% of users (low efficacy) and 3) inconsistent symptom improvement. To improve CPAP effectiveness, we propose to address novel phys- iologic targets that cause OSA in each individual: arousability, ventilatory control sensitivity and pharyngeal mus- cle compensation. Our overall objective is to determine the contribution of these traits to CPAP effectiveness independently of established biological, psychological and social predictors. This work leverages state-of-the art sleep study analysis tools and validated measures of the determinants of CPAP effectiveness to create a prag- matic, prospective cohort (n=267) of OSA patients. This unique dataset will help determine whether physiologic causes of OSA influence CPAP adherence, efficacy, sleep quality, symptoms, function and quality of life. The results will inform design and conduct of a randomized clinical trial designed to modify physiologic traits such as easy arousability to improve CPAP effectiveness and other patient-centered outcomes in OSA patients.
候选人。我的目标是成为一名独立的内科科学家,集生理学和医患学于一体

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREY ZINCHUK其他文献

ANDREY ZINCHUK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREY ZINCHUK', 18)}}的其他基金

Novel physiologiC prEdictors of Positive Airway Pressure effectiveness: NICE-PAP study.
气道正压有效性的新型生理预测因素:NICE-PAP 研究。
  • 批准号:
    10473795
  • 财政年份:
    2021
  • 资助金额:
    $ 17.23万
  • 项目类别:
Novel physiologiC prEdictors of Positive Airway Pressure effectiveness: NICE-PAP study.
气道正压有效性的新型生理预测因素:NICE-PAP 研究。
  • 批准号:
    10685994
  • 财政年份:
    2021
  • 资助金额:
    $ 17.23万
  • 项目类别:

相似海外基金

Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance
乙酰唑胺和醋甲唑胺对缺氧运动表现的影响
  • 批准号:
    572954-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 17.23万
  • 项目类别:
    University Undergraduate Student Research Awards
Acetazolamide to Improve Clinically Important Outcomes in Obstructive Sleep Apnea Patients with a High Loop Gain Endotype
乙酰唑胺可改善具有高环增益内型的阻塞性睡眠呼吸暂停患者的临床重要结果
  • 批准号:
    10524708
  • 财政年份:
    2022
  • 资助金额:
    $ 17.23万
  • 项目类别:
Development of a DNA Aptamer-Based Electrochemical Assay for Acetazolamide in Urine Using a Handheld Biosensor for Compliance Validation in Clinical Drug Trials
使用手持式生物传感器开发基于 DNA 适体的尿液中乙酰唑胺电化学检测方法,以验证临床药物试验的合规性
  • 批准号:
    9344796
  • 财政年份:
    2017
  • 资助金额:
    $ 17.23万
  • 项目类别:
Renoprotecion of acetazolamide and canagliflozin
乙酰唑胺和卡格列净的肾脏保护
  • 批准号:
    26461233
  • 财政年份:
    2014
  • 资助金额:
    $ 17.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Dichlorphenamide vs Acetazolamide for Periodic Paralysis
双氯苯那胺与乙酰唑胺治疗周期性麻痹
  • 批准号:
    6846379
  • 财政年份:
    2004
  • 资助金额:
    $ 17.23万
  • 项目类别:
Dichlorphenamide vs Acetazolamide for Periodic Paralysis
双氯苯那胺与乙酰唑胺治疗周期性麻痹
  • 批准号:
    7673808
  • 财政年份:
    2004
  • 资助金额:
    $ 17.23万
  • 项目类别:
Dichlorphenamide vs Acetazolamide for Periodic Paralysis
双氯苯那胺与乙酰唑胺治疗周期性麻痹
  • 批准号:
    7356429
  • 财政年份:
    2004
  • 资助金额:
    $ 17.23万
  • 项目类别:
Dichlorphenamide vs Acetazolamide for Periodic Paralysis
双氯苯那胺与乙酰唑胺治疗周期性麻痹
  • 批准号:
    7749961
  • 财政年份:
    2004
  • 资助金额:
    $ 17.23万
  • 项目类别:
Dichlorphenamide vs Acetazolamide for Periodic Paralysis
双氯苯酰胺与乙酰唑胺治疗周期性麻痹
  • 批准号:
    6723860
  • 财政年份:
    2004
  • 资助金额:
    $ 17.23万
  • 项目类别:
Sequential Changes of Cerebral Blood Flow after Acetazolamide Acetazolamide Loading in Hemodynamic Cerebral Ischemia: Relationship to Cerebral Oxygen Metabolism
血流动力学脑缺血中乙酰唑胺负荷后脑血流量的连续变化:与脑氧代谢的关系
  • 批准号:
    15591541
  • 财政年份:
    2003
  • 资助金额:
    $ 17.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了